Company retains an influential clinical collaborator for the launch of its innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that Adolfo Ramirez-Zamora, MD, has accepted to serve on neuropacs’ Board of Clinical Advisors, effective immediately.
Dr. Ramirez-Zamora is a Professor of Neurology, Program Director and Division Chief of Movement Disorders at the Norman Fixel Institute for Neurological Diseases at the University of Florida. The Fixel Institute works closely with the Center for Translational Research in Neurodegenerative Diseases and the McKnight Brain Institute at UF. Before joining UF, he practiced neurology at the Parkinson’s Disease and Movement Disorders Center at Albany Medical Center, where he served as the Philly E. Dake endowed chair in movement disorders. Dr. Ramirez-Zamora completed his neurology residency at Loyola University Chicago, followed by a fellowship in movement disorders at the University of California San Francisco. His clinical interests include developing and testing new therapeutic interventions in movement disorders and advancing the field of neuromodulation and neuroimaging techniques. His research interests are diverse but include exploring neurophysiological brain changes observed in neurodegenerative conditions, and the use of novel technologies, invasive and non-invasive neuromodulation approaches for the treatment of neurological diseases.
“Dr. Ramirez-Zamora brings contemporary expertise and clinical insights that encompass management of the entire spectrum of movement disorders, including Parkinson’s Disease,” stated Dr. Martin Handfield, neuropacs’ President and CEO. He added:” Dr. Ramirez-Zamora’s leadership experience will bring a unique vision to the Company. He has been involved in several leadership roles at the Parkinson’s Foundation, including the Hispanic Parkinson’s Advisory Council, outreach programs and the steering committee of the Parkinson’s Outcomes Project. He has served as a member of the Diversity Leadership Program and Science Committee at the American Academy of Neurology (AAN) and he is an active member of the Movement Disorders Society, National Ataxia Foundation, Parkinson Study Group, and Huntington Study Group”, Handfield concluded.
In response, Dr. Ramirez-Zamora’s commented: ” I’m thrilled with the opportunity to interface with neuropacs’ Founders and their Management Team, and I believe that neuropacs’ novel diagnostic tool and approach has the potential to change how several neurodegenerative diseases will soon be diagnosed, ultimately enabling earlier interventions, participation in clinical research and improved patient outcomes.”
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.